Effect of cardiac resynchronization therapy on myocardial gene expression in patients with nonischemic dilated cardiomyopathy.
ABSTRACT Cardiac resynchronization therapy (CRT) improves echocardiographic measures of ventricular structure and function in the failing heart. To determine whether or not these changes are representative of true biologic reverse ventricular remodeling or simply an artifact of an improved contraction pattern, we evaluated changes in myocardial gene expression typical of reverse remodeling before and after chronic CRT.
Optimally medically treated patients with nonischemic heart failure meeting standard clinical criteria for CRT were enrolled. Before implantation of a CRT device, baseline echocardiogram and endomyocardial biopsies were obtained. These studies were repeated after 6 months of CRT. Using quantitative reverse-transcriptase polymerase chain reaction, the amount of messenger RNA for selected genes regulating contractile function (sarcoplasmic reticulum Ca2+ ATPase, alpha- and beta-myosin heavy chain [MHC] isoforms, phospholamban [PLB]), and pathologic hypertrophy (beta-MHC and atrial natriuretic peptide [ANP]) was determined from biopsy samples. Changes in gene expression (baseline to 6 months) were determined and correlated to changes in echocardiographic remodeling parameters. Ten patients were enrolled in the study, with 7 completing both baseline and follow-up biopsies and echocardiograms. On average, a significant increase was observed in alpha-MHC and PLB gene expression from baseline to 6 months (P = .016 for both). Beta-MHC levels tended to decrease with CRT (P = .078). Increased alpha-MHC levels correlated best with decreases in left ventricular end-diastolic dimension (P = .073, r = -0.71) and reductions in mitral regurgitation. No significant correlation between ejection fraction and gene expression was found.
These changes in myocardial gene expression support the occurrence of reverse remodeling during chronic CRT. The changes are similar to those reported previously with beta-blockade, but were seen on top of standard drug therapies for heart failure.
- Antennas and Propagation Society International Symposium, 1976; 11/1976
Article: The year in heart failure[Show abstract] [Hide abstract]
ABSTRACT: Heart failure (HF) remains a dynamic field. Treatment continues to be refined and improved and, at last, there is evidence that the increased survival demonstrated in randomized clinical trial cohorts has been translated to the unselected general population. Beyond angiotensin-converting enzyme (ACE) inhibitors and beta-blockers, two more classes of drug, the angiotensin receptor blockers and aldosterone antagonists, were unequivocally demonstrated to have a survival benefit during 2003. This year also establishes a new era in device therapies, which also improve outcomes in patients with HF.Journal of the American College of Cardiology 01/2005; 44(12):2398-405. DOI:10.1016/j.jacc.2004.09.070 · 15.34 Impact Factor
- Journal of Cardiovascular Electrophysiology 10/2007; 18(10):1020-1. DOI:10.1111/j.1540-8167.2007.00947.x · 2.88 Impact Factor